#250: Hims & Hers Stock Plummets 35% – Is Now the Time to Buy?

This year has been a wild one for Hims & Hers. Thanks to the shortage of GLP-1 weight loss drugs such as Ozempic, Wegovy, and Zepbound, Hims was able to sell an unapproved compounded semaglutide. This caused sales to soar, with revenue up 95% in its most recent quarter. However, Hims' luck may have run out, as the U.S. FDA announced that the drug shortage is over and that it will clamp down on unapproved semaglutide. Is the sell-off justified, or is this a great time for investors to grab a piece of the pie?

Keeping with the bioscience theme, Emmet unpacks the recent sell-off of genetics company Illumina. Once a darling of the market—up 110x since its debut—the stock is now down 80% from its all-time high.

To wrap up, Mike and Emmet break down the recent announcement that deemed disposal and the higher ETF tax rate will be reviewed under Budget 2026. Let the Irish rejoice.

MyWallSt’s Horizon service follows founder, long-term investor, and beloved podcaster Emmet Savage. This week, Emmet will be pitching a stock that has seen revenue surge 200% since 2021 and has just secured a lucrative government contract.

A few lucky podcast listeners can grab an exclusive discount and unlock this stock and other future 100-baggers.

To grab this deal, email us at [email protected]

Don’t wait.

[email protected]

Become a successful investor by checking out all the content MyWallSt has to offer:

📩 Email us: [email protected]

📚 Learn the fundamentals of investing by downloading our free Learn app: https://bit.ly/3DXPOz7

💻 Keep updated on stock market news by visiting our blog: https://mywallst.com/blog/

🎧 Tune in to our podcast Stock Club to stay updated on weekly news: https://mywallst.com/stock-investment-podcast/

🎉 Follow MyWallSt on social:

🐦 Twitter: @MyWallStHQ

💃 TikTok: @MyWallSt

📸 Instagram: @MyWallSt

🖥️ Facebook: @MyWallSt

👔 LinkedIn: MyWallSt

00:00 Intro

05:30 Illumina: A Tale of Two Investors

26:55 Hims & Hers: Telehealth and Weight Loss Drugs

33:49 Hims & Hers: Earnings Report and Future Guidance

46:11 Irish Tax Changes and Investment Landscape

---

Hosted on Acast. See acast.com/privacy for more information.